Celcuity Inc. (NASDAQ:CELC) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its position in shares of Celcuity Inc. (NASDAQ:CELC) by 97.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 144,032 shares of the company’s stock after acquiring an additional 71,006 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Celcuity were worth $1,885,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Commonwealth Equity Services LLC grew its position in Celcuity by 9.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares during the last quarter. Acuta Capital Partners LLC boosted its position in shares of Celcuity by 3.6% during the third quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock worth $695,000 after buying an additional 1,600 shares during the period. nVerses Capital LLC bought a new position in Celcuity in the 3rd quarter worth approximately $33,000. Prospera Private Wealth LLC acquired a new stake in Celcuity in the 3rd quarter valued at approximately $35,000. Finally, Values First Advisors Inc. bought a new stake in Celcuity during the 3rd quarter valued at $86,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CELC shares. Stifel Nicolaus raised their price target on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 7th. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $29.17.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $10.93 on Friday. Celcuity Inc. has a twelve month low of $10.35 and a twelve month high of $22.19. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average of $12.78 and a two-hundred day moving average of $14.98. The company has a market capitalization of $405.83 million, a price-to-earnings ratio of -4.19 and a beta of 0.74.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.